フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs IRB approval to initiate Phase 2 study for methamphetamine abuse...
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19 Approximately 700 subjects participated in the...
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer Novel discovery and...
Revive Confirms No Material Undisclosed Information Toronto, Ontario, Canada -- August 12, 2021 -- InvestorsHub...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline Focusing on novel uses, production and delivery...
Revive Therapeutics Approved to Trade on the OTCQB Market TORONTO, June 25, 2021 -- InvestorsHub NewsWire -- Revive Therapeutics Ltd. ("Revive...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India TORONTO, June 8, 2021...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 TORONTO, Canada -- May 3...
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, March 24, 2021 -- InvestorsHub...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約